Bet on Earnings, No...
Health Care: Drugs
Biogen Idec Inc (BIIB: NASDAQ)
$210.80 3.05 | 1.47%
06/18/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 210.80 |
| 52 Week High | 242.64 |
| 52 Week Low | 134.00 |
| Avg. Daily Vol. (Mil) | 1.51 |
| Beta (3 year) | 1.23 |
| Share Related Items | |
| Mkt Cap (Mil) | 50,038.61 |
| Shares Out (Mil) | 237.37 |
| Float (Mil) | 213.30 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 1.30 |
| Current Ratio | 4.20 |
| LT Debt/ Equity | 0.10 |
| Total Debt / Equity | 0.12 |
| Valuation Ratios | |
| Price Earnings | 33.50 |
| Price/Sales | 11.81 |
| Price/Book | 6.82 |
| Price/Cash Flow | 26.60 |
| Per Share Data | |
| Earnings | 6.30 |
| Sales | 17.85 |
| Book Value | 30.92 |
| Cash Flow | 7.93 |
| Business Summary | |
|---|---|
| Biogen Idec Inc., is a global biotechnology company that discovers, develops, manufactures and markets therapies for the treatment of multiple sclerosis (MS) and other autoimmune disorders, neurodegenerative diseases and hemophilia. | |
| General Information | |
| 133 Boston Post Road
Weston, MA 02493 |
|
| www.biogenidec.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 5950 | |
| CEO: Dr. George A. Scangos,Ph | |
| Short Interest | |
| Current Month (Mil) | 2.77 |
| Previous Month (Mil) | 2.00 |
| Short Interest Ratio (Days) | 2.20 |
| Management Effectiveness | |
| Return on Equity | 20.50 |
| Return on Assets | 14.80 |
| Return on Investments | 18.70 |
| Profitability | |
| Gross Margin | 91.20 |
| EBIT Margin | 47.20 |
| Profit Margin | 35.50 |
Portfolios with BIIB
- Portfolio NameUser Type
- ProRenaissance Technologies
- User4 Overvalued Biotechs
- UserCorgies Follies
- ProNavellier & Associates
- UserMy SP portfolio
- ContributorDrugs Facing FDA Approval i...
- Contributor22 Biopharma Stocks With Br...
- UserKAREL VON ZOETE
- UserEverett Bishop Portfolio 1
- ProViking Global Investors
Latest BIIB Headlines from TheStreet
- Biogen Idec Inc (BIIB): Today's Featured Drugs Winner 06.18.13 | 05:06 pm
- Cramer's 6 Stocks in 60 Seconds: BIIB MTW AMAT GOOG RBS TSLA (Update 1) 06.12.13 | 05:06 pm
- Analysts' Actions: BIIB CLMT GPOR ORIG 06.12.13 | 08:06 am
- Biogen Idec Inc (BIIB): Today's Featured Drugs Laggard 06.10.13 | 05:06 pm
- 5 Drugs Stocks Dragging The Industry Down 06.10.13 | 01:06 pm
- Cramer's 6 Stocks in 60 Seconds: UAL MON GPS BIIB TIVO ACI (Update1) 06.07.13 | 05:06 pm
- 'Mad Money' Lightning Round: Amgen's Not a Fave 06.06.13 | 06:06 am
- Cramer's 'Mad Money' Recap: Profit While You Can 06.05.13 | 08:06 pm
- Biogen Idec Inc (BIIB): Today's Featured Health Care Laggard 06.03.13 | 05:06 pm
- Biogen Idec Inc (BIIB): Today's Featured Drugs Winner 05.24.13 | 05:05 pm
Press Releases for BIIB
- Image Of Biogen Idec's TECFIDERA(TM) (dimethyl Fumarate) Which Was Approved By The U.S. FDA On March 27, 2013 For Relapsing Multiple Sclerosis. (Photo: Business Wire) - Business Wire 03.27.13 | 04:03 pm
- CHMP Issues Positive Opinion For TECFIDERA™ (Dimethyl Fumarate) As A First-Line Treatment For Multiple Sclerosis In The European Union - Business Wire 03.22.13 | 08:03 am
- Positive Year One Results From Biogen Idec Phase 3 ADVANCE Trial Of PLEGRIDY™ (Peginterferon Beta-1a) Presented At AAN Meeting - Business Wire 03.20.13 | 07:03 am
- US Patent Office Grants Patent Claiming Dosing Regimen For TECFIDERA™ (Dimethyl Fumarate) - Business Wire 03.19.13 | 04:03 pm
- New TYSABRI Data Reaffirm Substantial Efficacy In Treatment Of People With MS And Demonstrate Stability Of Anti-JCV Antibody Status - Business Wire 03.18.13 | 07:03 am
- Biogen Idec To Present New Data On Diverse Neurological Portfolio At 65th AAN Annual Meeting - Business Wire 03.06.13 | 01:03 pm
- FDA Accepts Biogen Idec’s Biologics License Application For First Long-Lasting Factor IX Therapy For Hemophilia B - Business Wire 03.04.13 | 07:03 am
- Biogen Idec To Present At The Cowen And Company 33rd Annual Healthcare Conference - Business Wire 02.27.13 | 04:02 pm
- Biogen Idec To Present At The 2013 RBC Capital Markets Global Healthcare Conference - Business Wire 02.20.13 | 04:02 pm
- Biogen Idec To Present At The Citi 2013 Global Healthcare Conference - Business Wire 02.19.13 | 04:02 pm
Partner Headlines for BIIB
- Elan Is In Play - Seeking Alpha 06.15.13 | 05:06 am
- Encouraging Data on Novartis' Gilenya - Analyst Blog - Zacks 06.14.13 | 10:06 pm
- Stocks Open Mildly Higher; Myriad Continues To Slide - Investor's Business Daily 06.14.13 | 10:06 am
- Bull of the Day: Biogen (BIIB) - Bull of the Day - Zacks 06.14.13 | 09:06 am
- Amgen's Oncology Drug Meets Primary Endpoint - Analyst Blog - Zacks 06.14.13 | 12:06 am
- Royalty suffers setback in Elan poll - Financial Times 06.13.13 | 09:06 pm
- Myriad's Bearish Dive Shows Biotech Leaders Stalling - Investor's Business Daily 06.13.13 | 06:06 pm
- Market Close Report: NASDAQ Composite index closes at 3,400.43 down -36.52 points - NASDAQ 06.12.13 | 08:06 pm
- Stocks End Near Session Lows; But Rambus Jumps 6% - Investor's Business Daily 06.12.13 | 05:06 pm
- Stocks Fall Again As Correction Shows It Has Legs - Investor's Business Daily 06.12.13 | 04:06 pm
